Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global leader in cystic fibrosis (CF ... However, the company ...

OhioHealth Van Wert Hospital's Imaging Department has installed a new state-of-the-art Computed Tomography (CT) Unit to enhance diagnostic capabilities and provide high-level care close to home.

An $8 billion deal Shari Redstone struck with Skydance Media must go through the FCC next year. The new owners are seeking ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $418.00. The company’s shares opened today at $395.72.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Price Action: VRTX stock is down 13.4% at $387.37 at last check Thursday. UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and ...

2-Year U.S. Treasury Note Continuous Contract $102.691 0.059 0.06% 5-Year U.S. Treasury Note Continuous Contract $106.109-0.156-0.15% 10-Year U.S. Treasury Note Continuous Contract $108.578-0.438 ...

BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) for potential securities law violations. Investors who have lost money in ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people ...